Septerna, Inc. (Ticker: SEPN) is a pharmaceutical company focused on developing oral small molecule drugs targeting G protein-coupled receptors (GPCRs) for various therapeutic areas. The company’s lead candidate, SEP-876, is designed to treat hypoparathyroidism (a rare endocrine disorder where the body produces insufficient parathyroid hormone, leading to low calcium levels) and is currently in Phase 1 clinical trials. Septerna also has programs targeting chronic spontaneous urticaria (CSU, a skin condition causing recurring hives and swelling) and other mast cell diseases, as well as Graves' disease (an autoimmune disorder causing hyperthyroidism) and thyroid eye disease (TED, a condition causing inflammation and swelling behind the eyes, often related to Graves' disease).

Septerna will list on NASDAQ on October 25, 2024, offering 10.94 million shares at a price range of $15.00 to $17.00. The anticipated market capitalization at the offer price mid-point is approximately $591.04 million, with a total offer size of $175.0 million if priced at the midpoint of the range. The IPO is managed by J.P. Morgan, TD Cowen, Cantor Fitzgerald, and Wells Fargo Securities.